fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Oligorecurrent and oligoprogressive NSCLC

Written by | 22 Nov 2019

Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion……..    Written by Christine Clark.

Breastfeeding protects infants from antibiotic-resistant bacteria

Written by | 17 Nov 2019

A recent study completed at the University of Helsinki investigated the amount and quality of bacteria resistant to antibiotics in breast milk and the gut of mother-infant pairs,… read more.

Elderly have poor prognosis after recovery in long-term acute care hospitals

Written by | 17 Oct 2019

Most patients die within 5 years and spend two-thirds of remaining life as an inpatient.

IMW 2019: As treatment options explode, questions remain myriad in myeloma

Written by | 8 Oct 2019

Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.

Treating HL in the new millennium

Written by | 10 Sep 2019

Prof Peter Johnson (Southampton, UK) discusses where there is consensus and controversy in the management of HL in 2019, as well as talking about the key takeaways from his… read more.

Bridging the gap between clinical trial results and real-world myeloma practices

Written by | 5 May 2019

Professor Graham Jackson (Newcastle, UK) gives an overview of his presentation  on real world management of myeloma patients in the UK, with comments from Professor Sagar Lonial (Atlanta, USA). Professor Jackson… read more.

IBD around the world

Written by | 9 Apr 2019

IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation…

ASH 2018: Advances in the management of peripheral T-cell lymphoma

Written by | 5 Feb 2019

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is… read more.

ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

Written by | 14 Jan 2019

Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.

EHA 2018: Molecular profiling in multiple myeloma 

Written by | 3 Aug 2018

In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: The Issue of Frailty in MM

Written by | 24 Jun 2018

When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.